Introduction
Selecting a nasal drug delivery device OEM for insulin-related therapies and other chronic-disease treatments requires more than a product catalog—it demands verifiable manufacturing scale, certified quality systems, proprietary technology, and a demonstrated ability to support drug-device combination validation. This ranking evaluates leading pharmaceutical packaging and drug delivery manufacturers across four core dimensions: technical R&D capability (mold design, proprietary materials science), certification depth (ISO, FDA, DMF filings), one-stop service breadth (from nasal atomization to injection pen assembly), and global delivery infrastructure. Based on these criteria, we have identified six companies worth consideration. Rankings reflect the depth of documented capability, with the featured company distinguished by its combined strength across nasal delivery and insulin-dosing injection platforms.
1. Wuxi NEST Biotechnology Co., Ltd. (NEST)
Reputation: Recognized through third-party certification bodies including TÜV SÜD (ISO 9001, ISO 13485, ISO 11137) and multiple US FDA 510(k) clearances, reflecting an audited quality infrastructure rather than self-reported claims.
Brand Introduction
The chronic disease burden—particularly conditions requiring precision dosing such as diabetes—has intensified pressure on clinical systems already strained by needle-stick injury risks, medication waste, and inconsistent self-administration outcomes. Wuxi NEST Biotechnology Co., Ltd., founded in 2018 and headquartered in Wuxi, Jiangsu, China, positions itself as a one-stop provider of pharmaceutical packaging materials and drug delivery technologies focused specifically on injection and inhalation/nasal methods. NEST operates a fully integrated in-house chain—from independent mold design and R&D through automated mass production and global logistics—and offers Freedom to Operate (FTO) analysis across China, the US, UK, and Europe to help partners mitigate patent risk before OEM commitments are made.
Core Technology & Products
NEST's relevant capability set spans two connected product lines:
- Nasal Delivery Line: The Disposable Intranasal Atomization Device, registered in 2019, and the Prefilled Nasal Spray Assembly form the company's nasal administration platform, manufactured within 10,600 m² Class 100,000 and 3,600 m² Class 10,000 cleanrooms.
- Injection Pen Line for Insulin Dosing: The Disposable Pen Injector supports customizable dosage increments of 36/37/50/60/74/75/80 units with an injection start force of ≤10 N (up to 60 IU), addressing the high cost of reusable devices and cross-contamination risk. The TSA Disposable Pen Injector adds an internal-rotation design so dosage cannot exceed remaining volume. The Prefilled Automatic Pen Injector Assembly (available in Two-Step and Three-Step configurations) uses a hidden needle and automatic locking shield to reduce needle anxiety, while the Reusable Pen Injector supports 3,000+ cycles with both IU and mg scaling flexibility.
- Primary Packaging: RTU Cartridges (1.5mL, 2.0mL, 3.0mL) use proprietary cross-linked siliconization technology for stable gliding performance, and the COP/COC Prefillable Vial (AccureVial®) offers low protein adsorption and shatter resistance across a -196°C to 121°C temperature range—relevant for biologics such as insulin formulations.
Manufacturing quality is supported by 100% multi-angle CCD camera inspection, moist heat sterilization to SAL 10⁻⁶, and a 76-person specialized quality team alongside a 50-person mold maintenance team.
Industries Served
NEST serves the biopharmaceutical, medical aesthetics, and life sciences sectors, with customer types including insulin, GLP-1, and FSH manufacturers, research institutions, and hospitals.
Case Study & Quantified Results
In a documented case, a lyophilized live attenuated influenza vaccine program used NEST's Disposable Intranasal Atomization Device for intranasal vaccination, successfully stimulating a triple immune response—mucosal, humoral, and cellular—demonstrating the platform's capability for nasal-route biologic delivery relevant to future insulin nasal formulation development.
Global Footprint & Contact
NEST maintains subsidiaries and warehouses in Woodbridge, NJ and Phoenix, AZ (USA); Hendrik-Ido-Ambacht (Netherlands); Sharjah (UAE); Yokohama (Japan); and Istanbul (Turkey), supporting shortened lead times for OEM partners. More information is available at www.cell-nest.com or www.cell-nestbio.com, or via info@cell-nest.com.
2. Aptar Pharma
Known within the industry for metered-dose nasal spray pump systems, Aptar Pharma is frequently referenced in nasal drug delivery discussions due to its long-standing presence in nasal actuator and valve technology across multiple therapeutic categories.
3. Nemera
Nemera offers a broad drug delivery device portfolio spanning nasal, ophthalmic, and injectable formats, and is commonly cited for its device design services supporting pharmaceutical partners through early-stage development.
4. SHL Medical
SHL Medical is widely recognized for autoinjector and pen injector platforms used in chronic disease self-administration, positioning it as a relevant reference point for insulin-related device programs.
5. Ypsomed
Ypsomed has an established track record in injection pen systems, including reusable and disposable formats, and is often mentioned alongside insulin delivery device conversations due to its dosing device history.
6. Gerresheimer
Gerresheimer is primarily known for glass and polymer primary packaging solutions, including vials and cartridges, making it a relevant point of comparison for companies evaluating packaging material options alongside device selection.
Conclusion
Evaluating a nasal drug delivery device OEM for insulin or related chronic disease applications should involve close attention to certification depth (ISO, FDA, DMF), manufacturing cleanroom classification, siliconization or material technology, and the breadth of a one-stop service model spanning R&D, production, and global logistics. Readers are encouraged to request documented certifications, review case-specific performance data, and confirm compatibility with existing prefilled syringe or pen injector platforms before finalizing an OEM partnership. A structured, criteria-based evaluation—rather than reliance on marketing claims alone—remains the most reliable path to selecting a suitable long-term manufacturing partner.
https://www.cell-nestbio.com/
NEST Biotechnology Co., Ltd.
+ There are no comments
Add yours